A detailed history of Man Group PLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Man Group PLC holds 296,179 shares of NBIX stock, worth $40.1 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
296,179
Previous 233,225 26.99%
Holding current value
$40.1 Million
Previous $32.1 Million 6.2%
% of portfolio
0.09%
Previous 0.09%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $7.21 Million - $9.64 Million
62,954 Added 26.99%
296,179 $34.1 Million
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $7.4 Million - $8.1 Million
-56,536 Reduced 19.51%
233,225 $32.1 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $3.74 Million - $4.12 Million
-28,673 Reduced 9.0%
289,761 $40 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $1.7 Million - $2.13 Million
-16,058 Reduced 4.8%
318,434 $42 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $27.9 Million - $34.7 Million
-296,255 Reduced 46.97%
334,492 $37.6 Million
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $767,540 - $899,050
-8,573 Reduced 1.34%
630,747 $59.5 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $30.4 Million - $39.8 Million
323,350 Added 102.34%
639,320 $64.7 Million
Q4 2022

Feb 14, 2023

BUY
$106.72 - $127.06 $22.4 Million - $26.7 Million
210,283 Added 198.97%
315,970 $37.7 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $7.11 Million - $8.33 Million
77,245 Added 271.59%
105,687 $11.2 Million
Q2 2022

Aug 15, 2022

SELL
$75.79 - $100.07 $16.6 Million - $21.9 Million
-218,871 Reduced 88.5%
28,442 $2.77 Million
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $996,187 - $1.3 Million
13,750 Added 5.89%
247,313 $23.2 Million
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $18.6 Million - $24.8 Million
233,563 New
233,563 $19.9 Million
Q1 2021

May 17, 2021

SELL
$87.57 - $119.4 $184,509 - $251,575
-2,107 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$86.91 - $108.33 $16.2 Million - $20.2 Million
-186,516 Reduced 98.88%
2,107 $202,000
Q3 2020

Nov 16, 2020

BUY
$96.16 - $135.15 $9.02 Million - $12.7 Million
93,819 Added 98.96%
188,623 $18.1 Million
Q2 2020

Aug 14, 2020

BUY
$85.09 - $130.36 $4.01 Million - $6.15 Million
47,147 Added 98.93%
94,804 $11.6 Million
Q1 2020

May 15, 2020

BUY
$75.11 - $113.76 $2.63 Million - $3.98 Million
35,019 Added 277.09%
47,657 $4.12 Million
Q4 2019

Feb 18, 2020

BUY
$86.8 - $118.57 $442,593 - $604,588
5,099 Added 67.63%
12,638 $1.36 Million
Q3 2019

Nov 14, 2019

SELL
$83.82 - $101.5 $4.07 Million - $4.93 Million
-48,564 Reduced 86.56%
7,539 $679,000
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $2.17 Million - $2.74 Million
-30,075 Reduced 34.9%
56,103 $4.74 Million
Q1 2019

May 15, 2019

SELL
$69.31 - $91.53 $4.83 Million - $6.38 Million
-69,706 Reduced 44.72%
86,178 $7.59 Million
Q4 2018

Feb 14, 2019

BUY
$68.32 - $124.36 $9.65 Million - $17.6 Million
141,180 Added 960.15%
155,884 $11.1 Million
Q3 2018

Nov 14, 2018

SELL
$98.88 - $125.85 $259,065 - $329,727
-2,620 Reduced 15.12%
14,704 $1.81 Million
Q2 2018

Aug 14, 2018

SELL
$75.3 - $105.99 $385,912 - $543,198
-5,125 Reduced 22.83%
17,324 $1.7 Million
Q1 2018

May 15, 2018

BUY
$75.88 - $92.43 $1.7 Million - $2.07 Million
22,449 New
22,449 $1.86 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.